Amgen
Public profile▸✏️ Suggest a correction
📊 Financial
▾ 📰 Recent news
-
Up 231%, Is RTX Proving Why It Was a Mistake for Honeywell to Replace RTX in the Dow Jones Industrial Average?Honeywell was added to the Dow for its tech focus and diversification across different end markets.
-
Amgen : Statement on TAVNEOS® (avacopan)
Amgen Statement on TAVNEOS® On May 15, 2026, media outlets reported 20 deaths associated with patients being treated with TAVNEOS® in Japan. The report was based on a regulatory...
-
Amgen : 2026 Annual Meeting of Stockholders Presentation Non GAAP Reconciliations
Reconciliations Amgen Inc. GAAP to non-GAAP Reconciliations ...
-
Amgen's rare disease drug linked to deaths, liver injuries in Japan, WSJ reports
At least 20 people in Japan who tookAmgen's rare disease drug have died, while 22 othersdeveloped potentially fatal liver injuries, the Wall StreetJournal reported on Friday, citing partner...
-
'20 People in Japan Died After Taking Amgen Drug' - Wall Street Journal
https://www.wsj.com/health/pharma/20-people-in-japan-died-after-taking-amgen-drug-40edaefd?mod=Searchresults&pos=1&page=1
-
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
-
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaborationU.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.
-
Big Pharma deepens China drug partnerships amid biotech boomAngelica Peebles, CNBC Health and Pharmaceutical Reporter, says U.S. drugmakers are accelerating China partnerships as Bristol Myers expands biotech collaboration with Hengrui Pharma.
▾ 🧩 Sum of the parts
| Name | Type | % stake | Paid | Annual rev | Now worth | ×% our share | Note |
|---|---|---|---|---|---|---|---|
| Biopharmaceuticals | 🧩 segment | 100.0% | — | $30.0B | $170.0B | $170.0B | Core business encompassing research, development, manufacturing, and commercialization of human therapeutics. |
| Other | 🧩 segment | 100.0% | — | — | — | — | holdings not assigned to a reported segment |
| Deciphera Pharmaceuticals (select assets) · acq. 2024 | 🏢 subsidiary | 100.0% | $0.4B | — | $0.4B | $0.4B | Acquired select assets, including the rights to QINLOCK (ripretinib) in Europe, for gastrointestinal stromal tumor.(acquisition price) |
| Five Prime Therapeutics · acq. 2021 | 🏢 subsidiary | 100.0% | $1.9B | — | $2.0B | $2.0B | Acquired for its oncology asset, bemarituzumab.(acquisition price) |
| Horizon Therapeutics · acq. 2023 | 🏢 subsidiary | 100.0% | $27.8B | — | $28.0B | $28.0B | Acquired to expand Amgen's rare disease and inflammation portfolio.(acquisition price) |
| Otezla (from Celgene/BMS) · acq. 2019 | 🏢 subsidiary | 100.0% | $13.4B | — | $15.0B | $15.0B | Acquired the global rights to Otezla (apremilast) for psoriasis and psoriatic arthritis.(acquisition price) |
| Teneobio · acq. 2021 | 🏢 subsidiary | 100.0% | $0.9B | — | $1.0B | $1.0B | Acquired for its bispecific and multispecific antibody technologies.(acquisition price) |
▾ 📅 Calendar & events
No events yet. For public companies, earnings dates auto-populate. For private ones, anyone signed in can add events.
▾
💼 Famous stockholders
Institutional funds holding this stock per their most-recent SEC 13F filing. Click a fund name to jump to that investor's shadow page.
▸📺 Videos
· 8 · refreshed 2026-05-13 14:48
Top YouTube results for Amgen.
➕ Suggest a YouTube video
Your suggestion appears immediately for all visitors. Must be a public YouTube video relevant to Amgen.
🎬 Playlists featuring Amgen · 0
➕ Sign in to add a playlist. It surfaces here, on your personal playlists page, and on every twin course at every school.
💬 Quotes · 0
⭐ Reviews · 0
💭 Forum · Amgen
0replies inculture
Every shadow page is its own thread. Add a thought, reply to others, come back later.